

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Anton Uvarov
Date of last notice	19 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect
Nature of indirect interest (including registered holder)	(1) N/A (2) Held in spouse's name
Date of change	22 May 2023
No. of securities held prior to change	(1.1) 800,000 - UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) 900,000 - DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (1.3) 150,000 - PERFORMANCE SHARES CLASS C (1.4) 150,000 - PERFORMANCE SHARES CLASS D (1.5) 150,000 - PERFORMANCE SHARES CLASS E (1.6) 350,000 - ORDINARY FULLY PAID SHARES (2) 1,950,595 - ORDINARY FULLY PAID SHARES

⁺ See [chapter 19](#) for defined terms.

Class	(1.1) UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (1.3) PERFORMANCE SHARES CLASS C (1.4) PERFORMANCE SHARES CLASS D (1.5) PERFORMANCE SHARES CLASS E (1.6) ORDINARY FULLY PAID SHARES (2) ORDINARY FULLY PAID SHARES
Number acquired	(2) 49,405 - ORDINARY FULLY PAID SHARES
Number disposed	NIL
Value/Consideration	\$5,188
No. of securities held after change	(1.1) 800,000 - UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) 900,000 - DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (1.3) 150,000 - PERFORMANCE SHARES CLASS C (1.4) 150,000 - PERFORMANCE SHARES CLASS D (1.5) 150,000 - PERFORMANCE SHARES CLASS E (1.6) 350,000 - ORDINARY FULLY PAID SHARES (2) 2,000,000 - ORDINARY FULLY PAID SHARES
Nature of change	On market purchase

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

⁺ See [chapter 19](#) for defined terms.

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A